(19)
(11) EP 3 365 442 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
08.06.2022 Bulletin 2022/23

(45) Mention of the grant of the patent:
27.04.2022 Bulletin 2022/17

(21) Application number: 16858357.3

(22) Date of filing: 21.10.2016
(51) International Patent Classification (IPC): 
C12N 9/52(2006.01)
C07K 16/00(2006.01)
C12N 9/96(2006.01)
 C07K 14/705(2006.01)
C12N 9/64(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 14/705; C12N 9/6472; C07K 2319/70; C07K 2319/80; C07K 2317/32; C07K 2317/569; C07K 2317/622; C07K 16/005; C12N 9/96; C12N 9/52
(86) International application number:
PCT/US2016/058237
(87) International publication number:
WO 2017/070554 (27.04.2017 Gazette 2017/17)

(54)

METHODS TO CREATE CHEMICALLY-INDUCED DIMERIZING PROTEIN SYSTEMS FOR REGULATION OF CELLULAR EVENTS

VERFAHREN ZUR HERSTELLUNG CHEMISCH INDUZIERTER DIMERISIERUNGSPROTEINSYSTEME ZUR REGULIERUNG ZELLULÄRER EREIGNISSE

MÉTHODES POUR CRÉER DES SYSTÈMES DE PROTÉINES DE DIMÉRISATION INDUITE CHIMIQUEMENT POUR LA RÉGULATION D'ÉVÉNEMENTS CELLULAIRES

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 23.10.2015 US 201562245756 P

(43) Date of publication of application:
29.08.2018 Bulletin 2018/35

(73) Proprietor: Fred Hutchinson Cancer Center
Seattle, WA 98109 (US)

(72) Inventor:
  • AMIN, Rupesh
    Seattle, WA 98109 (US)

(74) Representative: Hobson, David James et al
Mathys & Squire The Shard 32 London Bridge Street
London SE1 9SG
London SE1 9SG (GB)


(56) References cited: : 
WO-A1-2004/046733
US-A1- 2003 162 249
US-A1- 2014 286 987
US-A1- 2015 086 576
 WO-A1-2015/150771
US-A1- 2013 059 359
US-A1- 2015 056 159
   
  • CHRISTOPHER G. PARKER ET AL: "An Antibody-Recruiting Small Molecule That Targets HIV gp120", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 131, no. 45, 18 November 2009 (2009-11-18), pages 16392-16394, XP055112393, ISSN: 0002-7863, DOI: 10.1021/ja9057647
  • STEFAN SEEBER ET AL: "A Robust High Throughput Platform to Generate Functional Recombinant Monoclonal Antibodies Using Rabbit B Cells from Peripheral Blood", PLOS ONE, vol. 9, no. 2, 4 February 2014 (2014-02-04), page e86184, XP055573450, DOI: 10.1371/journal.pone.0086184
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).